Compare SCM & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCM | TNXP |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 199.7M |
| IPO Year | 2012 | 2008 |
| Metric | SCM | TNXP |
|---|---|---|
| Price | $7.96 | $10.85 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 148.9K | ★ 413.4K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 14.22% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $0.33 | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $6.83 | $9.40 |
| 52 Week High | $13.55 | $25.69 |
| Indicator | SCM | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 33.24 |
| Support Level | $7.78 | $10.03 |
| Resistance Level | $8.92 | $12.99 |
| Average True Range (ATR) | 0.23 | 0.55 |
| MACD | -0.07 | -0.28 |
| Stochastic Oscillator | 16.07 | 10.01 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.